OBJECTIVES:: When across trial populations are heterogeneous, Matching-Adjusted Indirect Comparison (MAIC) can be used to assess comparative effectiveness; it is supported by NICE DSU guidance. The objective of these MAICs was to assess the comparative effectiveness of secukinumab (SEC; fully human anti-interleukin-17A) and infliximab (INF; tumor necrosis factor inhibitor [TNFi]) up to 1 year in biologic-naïve patients with PsA. METHODS:: Individual patient data from the SEC arms of FUTURE 2 (F2; SEC 150mg n=100; SEC 300mg n=100) were weighted to match baseline characteristics of the INF (5mg/kg) arm of IMPACT 2 (n=100). Another MAIC with pooled FUTURE 1 (F1) and F2 SEC 150mg data was also performed to maximize the effective sample size (ESS) for SEC. Matching parameters were: age, body weight, sex, race, presence of psoriasis, dactylitis, enthesitis, mean HAQ-DI score, methotrexate use and previous TNFi therapy. Recalculated outcomes from F2 [F1/F2] (SEC 150mg ESS=31[91]; SEC 300mg ESS=34; placebo, ESS=15[59]) were compared with IMPACT 2. American College of Rheumatology (ACR) 20, 50 and 70 responses were compared using odds ratios (ORs) at nearest equivalent time points across trials (week 54 [IMPACT 2] and week 52 [F1/F2]). Placebo-adjustment was not possible due to patients switching from placebo to active treatment. RESULTS:: At week 54/52, non-placebo-adjusted ACR 20 responses were higher with SEC 150mg than INF (OR [95% CI]: 5.24 [1.62–16.89], p=0.006) and ACR 20 and 50 responses higher with SEC 300mg (3.82 [1.38–10.60], p=0.010 and 4.97 [2.06–11.99], p<0.001, respectively) than INF. At week 54/52 in the pooled MAIC, ACR 20 and 50 responses were higher with SEC 150mg than INF (OR [95% CI]: 4.05 [1.98–